(2019-2.1.7-ERA-NET-2020-00005) Támogató: Nemzeti Kutatási, Fejlesztési és Innovációs
Hivatal
ERA PerMed(ERAPERMED2019-108)
(National Brain Programme 3.0(NAP2022-I-4/2022))
(TKP2021-EGA-25)
The fight against suicide is highly challenging as it may be one of the most complex
and, at the same time, most threatening among all psychiatric phenomena. In spite
of its huge impact, and despite advances in neurobiology research, understanding and
predicting suicide remains a major challenge for both researchers and clinicians.
To be able to identify those patients who are likely to engage in suicidal behaviors
and identify suicide risk in a reliable and timely manner, we need more specific,
novel biological and genetic markers/indicators to develop better screening and diagnostic
methods, and in the next step to utilize these molecules as intervention targets.
One such potential novel approach is offered by our increasing understanding of the
involvement of neuroinflammation based on multiple observations of increased proinflammatory
states underlying various psychiatric disorders, including suicidal behavior. The
present paper overviews our existing understanding of the association between suicide
and inflammation, including peripheral and central biomarkers, genetic and genomic
markers, and our current knowledge of intervention in suicide risk using treatments
influencing inflammation; also overviewing the next steps to be taken and obstacles
to be overcome before we can utilize cytokines in the treatment of suicidal behavior.